Dissecting the interactions of the ISG15-USP18-STAT2 inhibitory complex

This study elucidates the molecular mechanisms of the ISG15-USP18-STAT2 inhibitory complex by identifying a critical STAT2-binding loop in USP18, characterizing the impact of patient mutations and viral proteins on this interaction, and thereby advancing the understanding of type I interferon signaling regulation.

The Gist

The Big Picture: The Body's "Off Switch"

Imagine your body is a high-tech fortress. When a virus (like the flu or Zika) attacks, the fortress sounds an alarm called Type I Interferon (IFN). This alarm triggers a massive defense force (antiviral genes) to fight the invader.

But here's the problem: if the alarm keeps ringing forever, the fortress gets damaged by its own defenses. You need a way to turn the alarm off once the danger is under control.

This paper is about a specific "off switch" mechanism in your cells called the ISG15 Inhibitory Complex. It's a team of three proteins that work together to silence the alarm:

1. USP18: The main operator who flips the switch.
2. ISG15: The stabilizer that holds the switch in place.
3. STAT2: The messenger that carries the switch to the alarm panel.

The scientists wanted to know exactly how these three proteins hold hands to do their job. If they don't hold hands correctly, the alarm never turns off, leading to autoimmune diseases (where the body attacks itself).

---

The Detective Work: Building a 3D Puzzle

The researchers couldn't just look at these proteins under a regular microscope; they are too small and wiggly. So, they used a mix of high-tech tools:

• AlphaFold (The Digital Architect): They used a super-smart AI to build a virtual 3D model of how these proteins fit together. It's like using a computer program to predict how pieces of a Lego set snap together before you even build them.
• Cryo-EM (The Freeze-Frame Camera): They flash-froze the actual proteins to take a blurry, low-resolution photo. This confirmed that the AI's prediction was roughly correct.
• SPR (The Spring Scale): They used a machine that acts like a very sensitive spring scale to measure exactly how hard the proteins pull on each other. This told them how "sticky" the connection is.

The Big Discovery: The "Velcro Loop"

The most exciting finding was a specific part of the USP18 protein. The scientists discovered a unique little loop of amino acids (the building blocks of proteins) that acts like a specialized Velcro patch.

• The Analogy: Imagine USP18 is a backpack. For a long time, we knew it had a strap (ISG15) to hold it. But the scientists found a hidden Velcro loop on the back of the backpack.
• The Function: This loop is designed to stick only to a specific part of the STAT2 messenger. Without this specific loop, the backpack (USP18) can't grab the messenger (STAT2), and the "off switch" never gets delivered to the alarm panel.

They named this the STAT2 Binding Loop (SBL). It's the critical handshake that makes the whole team work.

Testing the Theory: Breaking and Fixing the Machine

To prove this loop was the key, the scientists played "Mad Scientist." They used genetic engineering to:

1. Break the Loop: They changed specific letters in the protein's code (mutations) to see what happened.
   • Result: When they messed up the Velcro loop, the proteins fell apart. The "off switch" failed. This explains why some patients with genetic mutations in this area get severe autoimmune diseases—their body can't turn off the alarm.
2. Strengthen the Loop: They also tried to make the Velcro stickier by changing a few amino acids to make the connection stronger.
   • Result: They created a version of the protein that held on even tighter. This is a huge deal because it suggests we might be able to design drugs that "tune" this switch. If we can make the switch stickier, we might be able to calm down an overactive immune system in diseases like lupus or cancer.

The Villains: How Viruses Try to Hack the System

Viruses are clever hackers. The paper also looked at how viruses like Zika and Influenza B try to break this system.

• The Hack: These viruses produce their own proteins (NS5 and NS1B) that try to grab onto the STAT2 messenger.
• The Surprise: The scientists found that these viral proteins don't just steal the messenger; they actually seem to join the party. They can bind to the ISG15-USP18-STAT2 team, forming a giant, four-person complex.
• The Implication: It's like the virus didn't just steal the off-switch; it built a fake off-switch that looks real but doesn't work. Or perhaps, it's holding the real switch hostage. Understanding this "quaternary complex" (a group of four) gives us new clues on how viruses hide from our immune system.

Why This Matters

This paper is like finding the instruction manual for a critical safety valve in a pressure cooker.

• For Patients: It explains exactly why certain genetic mutations cause severe immune diseases.
• For Doctors: It identifies specific "hotspots" (like that Velcro loop) where we could potentially design new drugs.
• For the Future: We might be able to create medicines that either tighten the switch (to stop autoimmune attacks) or loosen it (to help the immune system fight cancer or viruses better).

In short, the scientists took a complex, invisible molecular machine, figured out exactly how its gears mesh, and showed us how to fix it if it breaks.

Technical Summary

1. Problem Statement

The Type I interferon (IFN) signaling pathway is critical for antiviral defense but must be tightly regulated to prevent autoinflammation and interferonopathies. A key negative regulator is the ISG15-USP18-STAT2 inhibitory complex (ISG15 IC). While it is established that the deISGylase USP18, in complex with unconjugated ISG15, binds to STAT2 to suppress IFN signaling (likely by preventing IFNAR dimerization and displacing JAK1), the precise molecular architecture and structural determinants of this ternary complex assembly remain poorly understood. Furthermore, the impact of patient-derived mutations and viral evasion mechanisms on this complex's assembly and function requires further elucidation.

2. Methodology

The authors employed a multidisciplinary approach combining computational modeling, structural biology, and biophysical biochemistry:

• Protein Reconstitution: They purified individual components (ISG15, USP18, STAT2) and the ternary complex using the biGBac baculovirus expression system in High Five insect cells.
• Structural Modeling & Cryo-EM:
  • Cryo-EM: They attempted to solve the structure of the ternary complex. While they obtained a low-resolution map confirming the heterotrimeric nature, particle orientation bias prevented high-resolution reconstruction.
  • AlphaFold3: They utilized AlphaFold3 to generate a high-confidence (pTM: 0.7, iPTM: 0.69) structural model of the ISG15-USP18-STAT2 complex, which aligned with their low-resolution cryo-EM data.
• Biophysical Binding Assays:
  • Surface Plasmon Resonance (SPR): Used to quantitatively measure binding affinities ($K_D$) between STAT2 and ISG15-USP18, and to assess the impact of various mutations.
  • Fluorescence Polarization (FP): Used for qualitative and quantitative screening of binding interactions, including real-time assays to test the influence of viral proteins.
• Mutagenesis:
  • USP18: Designed site-directed mutants targeting a newly identified loop (SBL) and surrounding residues (hydrophobic and ionic) based on the AlphaFold model.
  • STAT2: Generated patient-derived mutations (e.g., R148Q, A219V) and rationally designed "gain-of-binding" mutants (e.g., L299W, A302W).
• Functional Assays:
  • Cleavage Assays: Tested if STAT2 binding alters USP18's catalytic deISGylase activity using proISG15 substrates.
  • Viral Interaction Studies: Investigated the binding of viral effector proteins (Zika virus NS5 and Influenza B virus NS1B) to the ISG15 IC.

3. Key Contributions & Results

A. Identification of the STAT2 Binding Loop (SBL)

• Phylogenetic analysis revealed that USP18 possesses a unique 10-amino acid insertion in its palm domain, termed the STAT2 Binding Loop (SBL), which is absent in closely related USP family members like USP30.
• USP30 (lacking the SBL) failed to bind STAT2, confirming the SBL is a critical specificity determinant.
• The AlphaFold model places the SBL on the back of the USP18 palm domain, forming a specific interface with the coiled-coil domain (CCD) of STAT2.

B. Molecular Determinants of the Interface

• USP18 Mutants: Systematic mutagenesis of the SBL and adjacent residues (e.g., D346, Y356, W358, E360) revealed that:
  • Hydrophobic residues (W358, Y356) and charged residues (D346, E360) are essential for binding.
  • The D346K mutation (disrupting an electrostatic bridge with STAT2 R148) and the Y356A/W358A double mutant nearly abolished binding.
  • The catalytically inactive USP18 (C64A) retained full STAT2 binding, confirming that deISGylase activity is not required for complex formation.
• STAT2 Mutants:
  • Patient Mutations: The A219V and R148Q mutations (associated with interferonopathies) severely disrupted or abolished USP18 binding.
  • Rational Engineering: The A302W mutation in STAT2 (introducing a hydrophobic residue to match USP18 W358) enhanced binding affinity ($K_D$ improved from ~0.31 µM to ~0.23 µM). Conversely, L299W weakened binding.

C. Functional Independence

• Catalytic Activity: Binding of STAT2 to the ISG15-USP18 complex did not inhibit USP18's deISGylase activity against proISG15 substrates, suggesting the inhibitory and catalytic functions are structurally distinct.

D. Viral Evasion Mechanisms

• Viral Proteins: Real-time FP assays demonstrated that viral proteins Zika virus NS5 and Influenza B virus NS1B can bind to the pre-formed ISG15 IC.
• Quaternary Complexes: The data suggests the formation of higher-order complexes (e.g., ISG15-USP18-STAT2-NS5), indicating that viral effectors may co-opt or modulate the host's negative regulatory machinery rather than simply displacing it.

4. Significance

• Structural Insight: This study provides the first detailed molecular map of the ISG15 IC assembly, identifying the SBL as a critical, unique feature of USP18 required for STAT2 recruitment.
• Clinical Relevance: The findings explain the pathogenicity of specific patient mutations (e.g., USP18 I60N, STAT2 R148Q) by demonstrating their direct disruption of the inhibitory complex, leading to uncontrolled IFN signaling.
• Therapeutic Potential: The ability to rationally engineer mutants with enhanced (A302W) or reduced binding affinities opens avenues for developing small-molecule therapeutics. These could potentially "tune" the IFN response—dampening it in autoimmune diseases or enhancing it in viral infections/cancer.
• Viral Pathogenesis: The discovery that viral proteins can form quaternary complexes with the ISG15 IC suggests a novel mechanism of immune evasion where viruses may stabilize or manipulate the host's negative feedback loop to their advantage.

In summary, the paper elucidates the structural basis of a critical immune checkpoint, linking specific amino acid interactions to disease phenotypes and viral evasion strategies, and provides a framework for future therapeutic modulation of the Type I interferon pathway.